The systemic inflammation response index (SIRI) predicts survival in advanced non-small cell lung cancer patients undergoing immunotherapy and the construction of a nomogram model
SIRI is an important independent predictor of early progression in advanced NSCLC patients treated with PD-1 inhibitors and may assist in identifying patients who will benefit from PD-1 inhibitors therapy in routine clinical practice.
Authors
- Hongwei Wu (ORCID: https://orcid.org/0000-0002-2816-749X)
- Tao Ren (ORCID: https://orcid.org/0000-0001-6641-4589)
- Tianlei Wang (ORCID: https://orcid.org/0000-0002-4498-4326)
- Long Liang (ORCID: https://orcid.org/0000-0002-0290-261X)
- Min Zhang (ORCID: https://orcid.org/0000-0002-1345-0604)
- Ke Xu (ORCID: https://orcid.org/0000-0001-5693-3959)
- Hongyuan Jia
- Chunhan Tang
Institutions
- University of Electronic Science and Technology of China (CN)
- Chengdu Medical College (CN)
- Sichuan Cancer Hospital (CN)
- First Affiliated Hospital of Chengdu Medical College (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-24
- DOI
- https://doi.org/10.3389/fimmu.2024.1516737
- Citations
- 13
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 3.67